Secondary childhood acute myeloid leukemia with complex karyotypic anomalies including monosomy 7, monosomy 5 and translocation (1;10) after I-131- metaiodobenzylguanidine therapy for relapsed neuroblastoma

Incesoy-Ozdemir S., Bozkurt C., Yuksek N., Oren A. C. , Sahin G., BOZKURT S. , ...Daha Fazla

TURKISH JOURNAL OF PEDIATRICS, cilt.53, sa.1, ss.83-86, 2011 (SCI İndekslerine Giren Dergi) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 53 Konu: 1
  • Basım Tarihi: 2011
  • Sayfa Sayıları: ss.83-86


The prognosis for relapsing or refractory neuroblastoma (NB) remains dismal, with a five-year disease-free survival of <20%, and no effective salvage treatment has been identified so far. I-131-metaiodobenzylguanidine (I-131-MIBG) has come to play an essential role in the imaging and therapy of NB over the past 30 years. The role of I-131-MIBG in the treatment of NB is continually expanding. I-131-MIBG treatment together with cumulative doses of other alkylating agents has potential serious late side effects such as myelodysplasia and leukemia, although rare. We describe a secondary acute myeloid leukemia case with complex karyotypic anomalies that included monosomy 5, monosomy 7 and translocation (1;10) in a child with relapsed NB who received therapeutic I-131-MIBG.